JAK inhibitors in 2019, synthetic review in 10 points

Romain Muller

DOI: https://doi.org/10.1016/j.ejim.2019.05.022

IF: 7.749

2019-08-01

European Journal of Internal Medicine

Abstract:<p>JAK inhibitors are recent treatments. Many publications have appeared in recent years, exposing treatment efficiencies in phases 2 and 3 studies, or their tolerance profile in various rheumatological diseases. We propose here a systematic review of JAK inhibitors, from their mechanism of physiological action up to the estimation of their current risk benefit balance, and their possible future applications.</p><p>In order to better synthesize the data, we organized this review into 10 essential points.</p><p>1- What is the role of JAK/Stat pathway?</p><p>2- How can a single signaling pathway regulate as many different signals?</p><p>3- What are the commercialized JAK inhibitors and their validated indications in humans today?</p><p>4- What is the level of efficiency of JAK inhibitors in inflammatory diseases?</p><p>5- What is the delay of efficiency of JAK inhibitors?</p><p>6- Where is the place of JAK inhibitors in the therapeutic strategy today?</p><p>7- What is the infectious tolerance profile of JAK inhibitors?</p><p>8- What is the non-infectious safety profile of JAK inhibitors?</p><p>9- What is the cost of JAK inhibitors compared to other DMARDs?</p><p>10- What future prospects for JAK inhibitors?</p>

medicine, general & internal